Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDR1 | Q08345 | 1/20 | 0.42 |
| ▸ | ASPH | Q12797 | 2/20 | 0.41 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.36 |
| ▸ | HPGD | P15428 | 2/20 | 0.36 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | AHR | P35869 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | XDH | P47989 | 1/20 | 0.33 |
| ▸ | KDM8 | Q8N371 | 1/20 | 0.32 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.32 |
| ▸ | RXRA | P19793 | 1/20 | 0.32 |
| ▸ | RXRB | P28702 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL29715665 | 0.98 | DDR1 (0.41) | DDR1ASPHNOTUMPOLBMAPT | |
| SCHEMBL18130158 | 0.85 | ASPH (0.35) | DDR1ASPHNOTUMPOLBMAPT | |
| SCHEMBL30147962 | 0.82 | DDR1 (0.41) | DDR1P2RX7HSD17B10GAAAHR | |
| SCHEMBL17057147 | 0.82 | DDR1 (0.41) | DDR1SMN1; SMN2P2RX7HSD17B10GAA | |
| SCHEMBL20304370 | 0.82 | PLK4 (0.42) | DDR1P2RX7HSD17B10GAAAHR | |
| SCHEMBL23853474 | 0.82 | DDR1 (0.39) | DDR1P2RX7HSD17B10GAAAHR | |
| SCHEMBL29106671 | 0.78 | TSHR (0.57) | DDR1POLBMAPTSMN1; SMN2KDM4E | |
| SCHEMBL353369 | 0.78 | DDR1 (0.47) | DDR1POLBP2RX7HSD17B10GAA | |
| SCHEMBL29913411 | 0.75 | MEN1 (0.43) | DDR1KDM4EHSD17B10GAAALDH1A1 | |
| Trifluoroacetic Acid SCHEMBL30591159 | 0.73 | MEN1 (0.55) | DDR1MAPTSMN1; SMN2KDM4EHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 92 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122076402-A | MOF molecular sieve adsorbent and preparation method and application thereof | — | 2026-05-26 | — | — | CN | claimed |
| CN-117551280-B | Fluorinated metal organic framework material for fluorine-containing electron special gas purification and preparation method thereof | 天津工业大学 | 2024-03-15 | — | — | CN | claimed |
| CN-117586522-A | Zinc metal organic framework material for separating ethane/ethylene mixed gas and preparation method thereof | 江西师范大学 | 2024-02-23 | — | — | CN | claimed |
| CN-117551280-A | Fluorinated metal organic framework material for fluorine-containing electron special gas purification and preparation method thereof | 天津工业大学 | 2024-02-13 | — | — | CN | claimed |
| US-20220128561-A1 | METHODS TO DETERMINE WHETHER A SUBJECT IS SUITABLE OF BEING TREATED WITH AN AGONIST OF SOLUBLE GYANYLYL CYCLASE (SGC) | BAYER AKTIENGESELLSCHAFT (DE) | 2022-04-28 | — | — | US | claimed |
| CN-107580495-A | The sGC stimulants, the sGC activators that combine individually and with PDE5 inhibitor are used for the purposes for treating the finger ulcer (DU) of adjoint system sclerosis (SSc) | 拜耳制药股份公司 | 2018-01-12 | — | — | CN | claimed |
| WO-2015095515-A1 | SGC ACTIVATORS FOR THE TREATMENT OF GLAUCOMA | NOVARTIS AG (CH) | 2015-06-25 | — | — | WO | claimed |
| EP-2401265-A2 | SOLUBLE GUANYLATE CYCLASE ACTIVATORS | Merck Sharp & Dohme Corp. (US) | 2012-01-04 | — | — | EP | claimed |
| CN-122076402-A | MOF molecular sieve adsorbent and preparation method and application thereof | — | 2026-05-26 | — | — | CN | disclosed |
| CN-116710439-B | Substituted pyrazolopiperidine carboxylic acids | BAYER AG (DE) | 2026-05-26 | — | — | CN | disclosed |
| CN-116829545-B | Substituted pyrazolylpiperidine carboxylic acids | 拜耳公司 | 2026-05-15 | — | — | CN | disclosed |
| US-12427131-B2 | Stimulators and/or activators of soluble guanylate cyclase (sGC) in combination with an inhibitor of neutral endopeptidase (NEP inhibitor) and/or an angiotensin AII antagonist and the use thereof | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2025-09-30 | — | — | US | disclosed |
| WO-2025072539-A1 | AMINO ACID COMPOUNDS WITH NITROGEN LINKERS AND USES THEREOF | PLIANT THERAPEUTICS, INC. (US) | 2025-04-03 | — | — | WO | disclosed |
| US-20250059196-A1 | TRICYCLIC DERIVATIVE INHIBITOR, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | JIANGSU HANSOH PHARMACEUTICAL GROUP CO., LTD. (CN) | 2025-02-20 | — | — | US | disclosed |
| US-20040235831-A1 | Composition for caring for the hair or the eyelashes, containing a pyrazolecarboxamide compound, use thereof for stimulating the growth of the hair and the eyelashes and/or for reducing their loss | SOCIETE L'OREAL, S.A. (FR) | 2004-11-25 | — | — | US | disclosed |
| WO-2004073594-A2 | USE OF AN INHIBITOR OF 15-HYDROXYPROSTAGLANDIN DEHYDROGENASE IN ORDER TO STIMULATE PIGMENTATION OF THE SKIN OR SKIN APPENDAGES | L'OREAL (FR) | 2004-09-02 | — | — | WO | disclosed |
| WO-2004047776-A1 | COMPOSITION FOR HAIR CARE OR EYELASHES CONTAINING A PYRAZOL-CARBOXAMIDE, ITS USE FOR STIMULATING HAIR AND EYELASH GROWTH AND/OR FOR PREVENTING LOSS THEREOF | L'OREAL (FR) | 2004-06-10 | — | — | WO | disclosed |
| EP-0151866-B1 | HERBICIDAL PYRAZOLE-(THIO)-CARBOXAMIDES | ELI LILLY AND COMPANY (US) | 1990-07-25 | — | — | EP | disclosed |
| US-4620865-A | Herbicidal and algicidal 1,5-disubstituted-1H-pyrazole-4-carboxamides | ELI LILLY AND COMPANY (US) | 1986-11-04 | — | — | US | disclosed |
| EP-0151866-A2 | Herbicidal pyrazole-(thio)-carboxamides | ELI LILLY AND COMPANY (US) | 1985-08-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250059196-A1 | TRICYCLIC DERIVATIVE INHIBITOR, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | WEE1, CYP51A1, WEE2 | DDR1 4869/4885ASPH 1494/4885NOTUM 4/4885 |
| US-12427131-B2 | Stimulators and/or activators of soluble guanylate cyclase (sGC) in combination with an inhibitor of neutral endopeptidase (NEP inhibitor) and/or an angiotensin AII antagonist and the use thereof | MME, ECE1, REN | DDR1 1272/4885ASPH 909/4885NOTUM 1566/4885 |
| US-20040235831-A1 | Composition for caring for the hair or the eyelashes, containing a pyrazolecarboxamide compound, use thereof for stimulating the growth of the hair and the eyelashes and/or for reducing their loss | BCOR, HCRTR1, RCOR1 | DDR1 1841/4885ASPH 2811/4885NOTUM 3109/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.